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hemokines are small cytokines primarily known for
their roles in inﬂammation. More recently, however,
they have been implicated in processes involved in
development of the granulation tissue of wounds, but little
is known about their functions during this process. Fibroblasts
play key roles in this phase of healing: some ﬁbroblasts
differentiate into myoﬁbroblasts, 
 
 
 
-smooth muscle actin
(SMA)-producing cells that are important in wound closure
and contraction. Here we show that the CXC chemokine
chicken chemotactic and angiogenic factor (cCAF) stimulates
ﬁbroblasts to produce high levels of 
 
 
 
-SMA and to contract
collagen gels more effectively than do normal ﬁbroblasts,
both characteristic properties of myoﬁbroblasts. Speciﬁc
inhibition of 
 
 
 
-SMA expression resulted in abrogation of
cCAF-induced contraction. Furthermore, application of cCAF
C
 
to wounds in vivo increases the number of myoﬁbroblasts
present in the granulation tissue and accelerates wound
closure and contraction. We also show that these effects in
culture and in vivo can be achieved by a peptide containing
the NH
 
2
 
-terminal 15 amino acids of the cCAF protein and
that inhibition of 
 
 
 
-SMA expression also results in inhibition
of N-peptide–induced collagen gel contraction. We propose
that chemokines are major contributors for the differentiation
of ﬁbroblasts into myoﬁbroblasts during formation of the
repair tissue. Because myoﬁbroblasts are important in
many pathological conditions, and because chemokines
and their receptors are amenable to pharmacological
manipulations, chemokine stimulation of myoﬁbroblast
differentiation may have implications for modulation of
functions of these cells in vivo.
 
Introduction
 
Chemokines are primarily known for their roles in inflamma-
tory and immune responses. However, these small cytokines
have also been shown to be upregulated during development
of the granulation tissue of wounds and to act on endothelial
cells and keratinocytes, cells that perform important functions
in the development of the healing tissue (Martins-Green and
Bissell, 1990; Nanney et al., 1995; Luster et al., 1998;
Martins-Green and Feugate, 1998). In addition to these cell
types, fibroblasts are also critical players during formation of
the granulation tissue. These cells are activated by cytokines
and growth factors that are released from platelets and
produced by macrophages. The activated fibroblasts prolif-
erate and migrate across the provisional matrix formed by
the fibrin–plasma fibronectin clot. As the clot is digested by
plasmin, fibroblasts replace it with cellular fibronectin, tena-
scin, and collagen III (Mackie et al., 1988; Clark, 1993),
molecules that are critical for migration of endothelial cells
and keratinocytes into the wound and for proper scar for-
mation. Some of the fibroblasts infiltrating the wound
differentiate to become myofibroblasts (Gabbiani, 1996;
Powell et al., 1999), cells that have bundles of 
 
 
 
-smooth
muscle actin (SMA)* and can contract, contributing to closure
of the wound (Germain et al., 1994; Lanning et al., 2000).
Chemokines are small, positively charged, secreted pro-
teins that consist of an NH
 
2
 
-terminal region of variable
conformation followed by a loop, three antiparallel 
 
 
 
strands, and a COOH-terminal 
 
 
 
 helix (Clark-Lewis et al.,
1995). They can be divided into four families based on the
position of the first two cysteines. The two major families
are the CXC family in which the two cysteines are separated
by any single amino acid (e.g., cCAF, interleukin [IL]-8,
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/melanocyte growth–stimulating activity [MGSA],
SDF-1, PF4, IP-10) and the CC family in which the two
cysteines are adjacent (MCPs, RANTES, Eotaxin, MIPs)
(Prieschl et al., 1995; Bazan et al., 1997; Zlotnik et al.,
1999). These proteins have no modifications other than two
disulfide bonds and are multifunctional. Chemokines func-
tion in a very tightly regulated dose- and time-dependent
manner, strongly suggesting that their actions are affected by
the microenvironmental conditions (Dunleavy and Couch-
man, 1995; Gharaee-Kermani et al., 1996; Rennekampff et
al., 1997; Young et al., 1997).
The first evidence that chemokines are associated with
healing was reported in 1990 when it was shown that the
chemokine chicken chemotactic and angiogenic factor
(cCAF) is overexpressed during wound healing (Martins-
Green and Bissell, 1990). This chemokine is highly ex-
pressed in the first 24–48 h after injury and remains elevated
for at least 16 d after wounding (Martins-Green and Bissell,
1990; Martins-Green et al., 1992; Martins-Green and Ha-
nafusa, 1997). It is primarily expressed by the fibroblasts of
the granulation tissue, especially where interstitial collagen is
abundant and by the endothelial cells of microvessels of the
granulation tissue (Martins-Green and Bissell 1990; Mar-
tins-Green et al., 1996).
In the chicken chorioallantoic membrane (CAM) assay, at
low doses cCAF is chemotactic for monocyte/macrophages
and lymphocytes and after several days of exposure to this
chemokine, the ectoderm of the CAM becomes thickened
and a granulation-like tissue develops beneath the cCAF-
containing pellet. In this granulation-like tissue, there is an
increase in the amount of interstitial collagen and the fibro-
blasts in the mesoderm are consistently aligned with the col-
lagen fibers and appear to cause tissue contraction (Mar-
tins-Green and Feugate, 1998). At high concentrations,
however, cCAF stimulates blood vessel sprouting from the pre-
existing vessels of the CAM (angiogenesis) in the absence of
leukocyte chemotaxis (Martins-Green and Feugate, 1998).
Other CXC chemokines have also been associated with
wound-healing events. For example, in burn wounds, gro
 
 
 
/
MGSA is expressed by keratinocytes as they differentiate af-
ter reepithelialization of the wound. Furthermore, CXCR2,
the receptor for MGSA, is present in migrating and prolifer-
ating keratinocytes (Nanney et al., 1995; Rennekampff et
al., 1997). In the granulation tissue, MGSA expression is as-
sociated with fibroblasts, smooth muscle cells/myofibro-
blasts, and a subpopulation of macrophages (Nanney et al.,
1995). This pattern of expression strongly suggests a role of
this chemokine in healing of burn wounds. It also has been
shown that in transgenic mice expressing IP-10, a CXC
chemokine that inhibits angiogenesis, wounds heal poorly
and exhibit defects in development of the granulation tissue
(Luster et al., 1998).
It is becoming increasingly more evident that chemo-
kines are expressed at the sites of injury and that they affect
processes involving proper development of the granulation
tissue. Fibroblasts are critical participants in the develop-
ment of this healing tissue and they also express high levels
of chemokines upon stimulation by stress-inducing agents
such as those released upon wounding. Despite this correl-
ative evidence, little is known about how these small cyto-
kines affect wound fibroblast function. cCAF is highly ex-
pressed by the fibroblasts of healing tissue, stimulates the
formation of granulation-like tissue in the CAM, and is
highly homologous to several human chemokines (Stoeckle
and Barker, 1990). Therefore, we investigated the effects of
this chemokine on proliferation and differentiation of fi-
broblasts, both important processes during granulation tis-
sue development. We find that cCAF stimulates fibroblasts
to differentiate into myofibroblasts and accelerates wound
closure in vivo
 
.
Figure 1. The effects of cCAF on fibroblast growth. (A) Primary 
connective tissue embryonic fibroblasts were treated for 3 d with 
increasing doses of cCAF. Treatment was applied every 24 h. cCAF 
suppresses fibroblast proliferation in a dose-dependent pattern 
characteristic of most chemokine functions. Maximum suppression 
was observed at a dose of 750 ng/ml. (B) Inhibition of cCAF function 
with an antibody specific to this chemokine abrogates this suppression 
of growth. Results shown are representative of several independent 
experiments. Double asterisk indicates P   0.01; Asterisk indicates 
P   0.05. 
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Results
 
Effects of cCAF on fibroblast growth
 
To determine the effects of cCAF on fibroblast growth, pri-
mary chicken embryonic connective tissue fibroblasts were
cultured in the presence of 2% donor calf serum. Embryonic
fibroblasts behave much like wound fibroblasts (Brown et
al., 1993), and the presence of a small amount of serum in
the medium mimics the conditions of the wound, where se-
rum factors are abundant. Because these are primary fibro-
blasts isolated weekly from different embryos, rather than
cell lines, there are genetic variations and therefore differ-
ences in the levels of response to the various treatments. As a
consequence, internal controls were always included and re-
sults from different batches of cells were not averaged.
Therefore, all figures depict a representative experiment out
of several performed for each type of experiment.
When fibroblasts are cultured in the presence of serum,
cCAF suppresses proliferation of these cells by 25% com-
pared with untreated cells (Fig. 1; 
 
P
 
 
 
  
 
0.01). This effect is
dose dependent, with the greatest suppression occurring at
500–750 ng cCAF/ml medium (Fig. 1 A), and at 2 d after
plating (unpublished data). It is commonly observed that
chemokines cause their effects only in a narrow range of
concentrations; at concentrations higher than the optimal
dose, their receptors are very quickly desensitized and/or
downregulated (e.g., Zlotnik et al., 1999; Murdoch and
Finn, 2000). Although chemokine concentrations of 10
 
 
 
2
 
–
10 ng/ml can chemoattract and activate leukocytes, chemo-
kines acting on other cell types such as endothelial cells,
smooth muscle cells and fibroblasts require concentrations
in the range of 10
 
2 
 
ng/ml (Gupta and Singh, 1994; Gharaee-
Kermani et al., 1996; Luo et al., 1996). This is within phys-
iological range; wound fluid from burn patients has MGSA
concentrations of 10
 
2
 
–10
 
3 
 
ng/ml at 6–7 d after injury
(Rennekampff et al., 1997). Experiments using an antibody
specific for cCAF showed that this antibody abrogates the
effects of this chemokine on proliferation (Fig. 1 B).
Although the decrease in growth induced by cCAF is signif-
icant, it is not large. Therefore, we examined the possibility
that this reduction in cell numbers was due to increased cell
death. Cells grown under the same conditions as above were
prepared to detect apoptosis by determining whether DNA
laddering occurs. Both untreated fibroblasts and those treated
with cCAF had intact DNA (Fig. 2 A), showing that this che-
mokine did not induce cells to undergo apoptosis. Similar
studies performed to detect whether cCAF induced necrotic
cell death using trypan blue showed that this chemokine does
not cause cells to undergo necrosis (Fig. 2 B).
We have shown previously that the COOH-terminal pep-
tide (28 amino acids) of cCAF is by itself angiogenic in vivo
(Martins-Green and Feugate, 1998; Martins-Green and Kelly,
1998). Therefore, we tested the possibility that these effects of
cCAF on fibroblast growth are also mediated by the COOH
terminus of the molecule. Cells were treated with the
COOH-terminal peptide following the same regimen of
treatment as for cCAF; we found that this peptide did not
cause a decrease in cell numbers (Fig. 3). We then turned to
the NH
 
2
 
 terminus of the molecule because it has been shown
for several chemokines that their chemotactic properties for
leukocytes require this portion of the protein (Clark-Lewis et
al., 1995; Strieter et al., 1995; Weber et al., 1996; Baggiolini
et al., 1997; Martins-Green and Feugate, 1998). Treatment of
fibroblasts with the first 15 amino acids of the NH
 
2
 
 terminus
(N-peptide) resulted in a decrease in growth similar to that in-
duced by cCAF (Fig. 3). Furthermore, the dose- and time-
dependent pattern of suppression of growth induced by the
N-peptide was the same as that of the whole cCAF molecule,
albeit at a higher molar concentration (unpublished data).
 
cCAF stimulates 
 
 
 
-SMA expression
 
The results described above show that the decrease in cell
numbers induced by cCAF is specific and not due to cell
Figure 2. The effects of cCAF on cell death. (A) To detect cCAF-
induced apoptosis we used the DNA Laddering Detection system 
from Roche Biochem. Fibroblasts were plated, treated as described 
in Materials and methods, the DNA was prepared as suggested by 
the manufacturer, and agarose gel electrophoresis was performed. 
No DNA laddering was detected in cells treated with cCAF, N-peptide, 
or C-peptide. The positive control for DNA laddering provided by 
the manufacturer consisted of U937 cells treated for 3 h with camp-
tothecin (4  g/ml). (B) Cells incubated with trypan blue, which stains 
necrotic cells blue, showed that cCAF does not stimulate cell death 
by necrosis. The results shown represent one of three experiments. 
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death, but that the effect is small and requires 2–3 d to be
detected, even with repeated applications of cCAF. This
could mean that cCAF plays a role in triggering fibroblasts
to slow down growth and develop a differentiated pheno-
type with a consequent decrease in cell division. Therefore,
we investigated the possibility that cCAF stimulates differen-
tiation of fibroblasts into myofibroblasts, cells that play an
important role in wound closure and proliferate at a slower
rate than normal fibroblasts (Masur et al., 1996; Nedelec et
al., 1998; Dimitrijevic-Bussod et al., 1999; Khouw et al.,
1999). Immunolabeling of cCAF-treated fibroblasts with an
antibody specific for 
 
 
 
-SMA, a marker for myofibroblasts,
revealed the presence of many cells showing intense stain-
ing for fiber bundles, whereas control cells showed fewer
and less brightly stained fibers (Fig. 4, A and B). As was
found for the growth studies, treatment with the NH
 
2
 
-ter-
minal peptide stimulated 
 
 
 
-SMA production, whereas the
COOH-terminal peptide did not (Fig. 4, C and D). Immu-
noblot analysis of cell extracts using this antibody showed
increased levels of 
 
 
 
-SMA in cells treated with cCAF or the
N-peptide compared with cells treated with the C-peptide
and control cells (Fig. 4 E). Inhibition of cCAF or N-pep-
tide function by treatment of the cells in the presence of the
cCAF antibody abrogated the increase in 
 
 
 
-SMA expression
(Fig. 4, F and G).
Although 
 
 
 
-SMA is considered the characteristic marker
for myofibroblasts, vimentin, desmin, and myosin heavy
chain, as well the muscle proteins myoD and myogenin, are
sometimes expressed by myofibroblasts (Skalli et al., 1989;
Mayer and Leinwand, 1997). Using antibodies recognizing
the chicken proteins, we immunoblotted cell extracts from
cCAF and N-peptide–treated fibroblasts. There was no de-
tectable desmin, myosin heavy chain, or myoD present in ei-
ther control or treated cells (unpublished data). However,
vimentin levels increased with cCAF or N-peptide treatment
in a manner similar to that observed for 
 
 
 
-SMA (Fig. 5). Al-
though desmin and the sarcomeric proteins myoD and
MHC are expressed in some myofibroblasts, their presence
or absence depends on the origin of the myofibroblasts,
whereas most myofibroblasts express both vimentin and
 
 
 
-SMA (Gabbiani, 1994).
To determine whether this increase in 
 
 
 
-SMA and vimen-
tin results in a functional phenotype, we examined the effect
of cCAF on contraction of fibroblast-seeded collagen gels.
Fibroblasts plated on collagen often grow in clusters, but cel-
lular clusters in plates treated with cCAF or N-peptide were
more contracted than clusters in control cells (Fig. 6, A–C).
When collagen gels were released after 4–5 d of treatment,
cCAF or N-peptide–treated cells contracted the gels more
tightly than did untreated cells (Fig. 6, D–F). Immunolabel-
ing of sections prepared from collagen gels with the antibody
to 
 
 
 
-SMA showed that treated gels contain more cells with
fibers staining for 
 
 
 
-SMA than control gels (Fig. 6, G–I).
Fig. 6 J shows a quantitative analysis of cCAF- and of
N-peptide–induced collagen gel contraction. To demonstrate
that this contraction is the result of an increase in 
 
 
 
-SMA
expression, we treated the cells with phosphorothioate anti-
sense oligodeoxyribonucleotides (ODN) to inhibit produc-
tion of 
 
 
 
SMA. Antisense ODN strongly decreased the abil-
ity of the cells treated with cCAF or the N-peptide to
contract the collagen gels, but did not have an effect on the
contractility of cells treated with the COOH terminus (Fig.
7 A). Detection of 
 
 
 
-SMA in these gels shows that the levels
of this protein in the gels treated with antisense oligonucle-
otides is similar to those of the control, whereas the levels in
the gels treated with cCAF or the N-peptide alone or in the
presence of sense oligonucleotides, have higher levels of
 
 
 
SMA (Fig. 7 B).
T
 
 
 
 determine whether cCAF directly stimulates 
 
 
 
-SMA
mRNA expression, we used reverse transcription (RT)-PCR
with specific primers to this molecule to examine the effects
of cCAF on mRNA levels. This chemokine causes an in-
crease in 
 
 
 
-SMA mRNA levels within 1 h of treatment, and
mRNA levels remain elevated for more than 12 h after treat-
ment (Fig. 8).
 
cCAF-induced effects on wound closure
 
In wounded tissue, myofibroblast differentiation contributes
to closing of wounds (Nedelec et al., 1998). Our finding
that cCAF stimulates fibroblasts to acquire myofibroblastic
Figure 3. Effects of the C- and N-peptides of the cCAF protein on 
fibroblast growth. Treatment with the C-peptide (28 amino acids) 
did not suppress the growth of connective tissue fibroblasts, 
whereas treatment with the N-peptide (15 amino acids) suppresses 
the growth of fibroblasts to a level similar to that caused by the 
whole cCAF molecule. Results shown are representative of three 
independent experiments. Asterisk indicates P   0.05. 
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phenotype and function in culture led us to determine
whether cCAF affects wound closure in vivo. Full thickness
and same size excision wounds were made on the underside
of wings of 2-wk-old chicks, and for each bird one wing was
treated with vehicle (H
 
2
 
O) and the other with 1 
 
 
 
g of cCAF
every other day. The bandages were removed at days 3, 5,
and 7, the wounds were photographed, dressed with clean
bandages, and treatments applied. For each wound, rate of
wound closure was examined by taking digital photographs
of the same wound through time and then determining the
areas of the wounds from the photographs using NIH Im-
age. Fig. 9, A and C, show a wounded wing before and after
3 d of treatment with vehicle, whereas Figs. 9, B and D,
show the contralateral wing of the same bird, treated with
cCAF at the same times. Fig. 9 E shows the results of ana-
lyzes and comparison of the wound areas of several birds
over time
 
.
 
 On day 3, the cCAF-treated wounds had closed
to a significantly greater degree than the vehicle-treated
wounds. At day 5, the closure of the control wounds was still
less than that of the experimental wounds, but closure in the
controls may have accelerated during this period. Although
cCAF-treated wounds close faster, by day 7 both control and
treated wounds were completely closed. Wounds treated
with the N-peptide also showed accelerated wound closure
during days 0–3, albeit less strongly than with the whole
cCAF molecule (Fig. 9 F).
Sections through the wounds show that the granulation
tissue of cCAF-treated wounds appears more dense earlier
in wound healing (days 3 and 5) than the tissue of the
wounds treated with vehicle (Fig. 10, A–D). In particu-
lar, the granulation tissue of the control wounds at day 5
(Fig. 10 C) resembles that of the treated on day 3 (Fig. 10
B). By day 7, the cCAF-treated wounds appear to be al-
ready remodeling, whereas those treated with vehicle
looked much like the granulation tissue of cCAF-treated
wounds at 5 d (Fig. 10, E and F). It is known that wound
Figure 4. Effect of cCAF and the NH2 
terminus on  -SMA expression. (A) 
Untreated embryonic connective tissue 
fibroblasts were immunolabeled for 
 -SMA, a marker for myofibroblast 
differentiation. Some fibroblasts show a 
small amount of staining for this protein, 
which is characteristic of fibroblasts in 
culture. (B) Cultures treated with cCAF 
or (C) with the N-peptide for 3 d show 
that more fibroblasts are stained for 
 -SMA, that more fibrils are present in 
the cells, and that the staining is more 
intense than for untreated cells or those 
treated with the C-peptide (D). (E) 
Immunoblot analysis for  -SMA to 
quantify the results observed in (A–D). 
All lanes in the immunoblots contain 
equal amounts of total protein, as 
measured by the DC protein assay (Bio-
Rad Laboratories). Cells treated with 750 
ng/ml of cCAF or of the N-peptide show 
much higher levels of  -SMA when 
compared with untreated or C-peptide–
treated cells. n   4 and asterisk indicates 
P   0.05. Inhibition of cCAF (F) or 
N-peptide (G) with an anti-cCAF anti-
body blocks the increase in  -SMA 
expression. Results shown in E, F, and G 
are representative of three or more 
experiments. 
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contraction causes the healing tissue to become more
dense and compact, therefore our findings strongly sug-
gest that cCAF stimulates early wound contraction and
closure.
To test whether this acceleration in wound closure was due
to an increase in the number of myofibroblasts in the granula-
tion tissue, we immunostained vehicle-treated and cCAF-
treated wounds for 
 
 
 
-SMA (Fig. 11). At day 3, the granula-
tion tissue of the cCAF-treated wounds has many more cells
that label for 
 
 
 
-SMA (Fig. 11 B) than does the tissue of vehi-
cle-treated wounds (Fig. 11 A). On day 5, there continue to
be many more cells staining for 
 
 
 
-SMA in the cCAF-treated
wounds (Fig. 11 D) than in the control tissue (Fig. 11 C). By
day 7, this difference has greatly decreased; the treated and
untreated wounds have similar staining for myofibroblasts
(Fig. 11, E and F). Quantification of the number of cells la-
beling for 
 
 
 
-SMA in the wounds shows that there are signifi-
cantly more myofibroblasts in the cCAF-treated wounds at
days 3 and 5, but the difference is no longer significant by day
7 (Fig. 11 G). The amount of 
 
 
 
-SMA in the wounds was not
quantified by Western blotting because wounds treated with
cCAF contain many more new blood vessels that are sur-
rounded by cells that express 
 
 
 
-SMA. Whereas it is easy to
distinguish the blood vessel–associated cells that contain
 
 
 
-SMA from myofibroblasts in the granulation tissue by mi-
croscopy, we would not be able to make that distinction by
immunoblot analysis. The earlier appearance of 
 
 
 
-SMA–stain-
ing cells in wounds treated with cCAF suggests that the ac-
celeration of wound contraction by cCAF is due to an in-
crease in myofibroblasts at the early stages of wound repair.
Figure 5. Effect of cCAF and the NH2 terminus on vimentin 
expression. Immunoblot analysis for vimentin, another marker for 
myofibroblasts. Cells treated with 750 ng/ml of cCAF or of the 
N-peptide show higher levels of vimentin than do untreated or 
C-peptide–treated cells. All lanes contain equal amounts of total 
protein, as measured by the DC protein assay (Bio-Rad Laboratories).
Figure 6. Increase in collagen gel 
contraction by fibroblasts treated with 
cCAF. (A–C) Untreated fibroblasts plated 
on collagen gels form loose clusters (A), 
whereas fibroblasts treated with cCAF 
(B) or N-peptide (C) form clusters that 
are much tighter and generally pull 
away from the collagen. (D–F) Collagen 
gels, after release from the edge of the 
culture dish, show moderate contraction 
for untreated cells (D) but much greater 
contraction for cells treated with cCAF 
(E) or N-peptide (F). (G–I) Sections 
through the gels depicted in D–F were 
immunolabeled for  -SMA to show the 
presence of cells containing  -SMA. The 
staining is much less intense in untreated 
cells (G) than in cells treated with cCAF (H) or N-peptide (I). (J) Contracted gels were photographed and their areas were measured and analyzed 
using NIH Image. Treatments with both cCAF and N-peptide stimulated fibroblasts to contract gels more efficiently than did untreated cells. 
Asterisk indicates P   0.05. Bars, 100  m. 
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Discussion
 
The work presented here shows that the CXC chemo-
kine, cCAF, when applied repeatedly, suppresses fibroblast
growth to 
 
 
 
75% of untreated cells, in a time- and dose-
dependent manner. This decrease in growth is not due to
cell death but rather it correlates with cCAF-induced expression
of the myofibroblast marker, 
 
 
 
-SMA. Although the decrease
in proliferation takes time to be detected, 
 
 
 
-SMA expres-
sion levels rise rapidly following cCAF treatment, strongly
suggesting that this chemokine stimulates myofibroblast
differentiation directly. The expression of 
 
 
 
-SMA in
cCAF-treated cells results in an increase in the ability of the
fibroblasts to contract collagen gels. Specific inhibition of
 
 
 
-SMA expression resulted in abrogation of contraction. All
of these effects are specific and can be accomplished by the
NH
 
2
 
-terminal peptide of the cCAF molecule by itself. Fur-
thermore, in vivo, when applied to excision wounds, this
chemokine accelerates wound closure and the granulation
tissue becomes more dense early in wound healing. This cor-
relates with an increase in the number of myofibroblasts in
the tissue. These results indicate that cCAF stimulates fibro-
blasts to differentiate into myofibroblasts and strongly sug-
gest that this function may be responsible for the more effec-
tive wound closure induced by this chemokine.
Although little is known about chemokines and wound
closure, expression of cCAF, IL-8, and MGSA is elevated
until wound closure and then decreases to low but still ele-
vated levels during granulation tissue formation (Martins-
Green and Bissell, 1990; Engelhardt et al., 1998). In addi-
tion, knockout mice for CXCR2, a receptor for IL-8 and
MGSA, exhibit delayed wound closure (Devalaraja et al.,
2000). The results presented here shine light into these find-
ing in vivo. Our observations suggesting that cCAF stimu-
lates 
 
 
 
-SMA expression directly, that this elevation in ex-
pression leads to increased contraction of collagen gels and
to more rapid wound contraction and closure, indicate that
chemokines potentially play significant roles in formation of
the granulation tissue of wounds. Furthermore, the small
(15 amino acids) NH
 
2
 
-terminal peptide of the cCAF mole-
cule has the same effects, suggesting that similar behavior in
a human chemokine could be a promising target in design-
ing drugs that affect the differentiation of myofibroblasts.
It has been shown that myofibroblasts can differentiate
from fibroblasts when these cells are exposed to TGF
 
 
 
1 in
culture (Desmouliere et al., 1993) and that, in vivo, this
growth factor directly stimulates myofibroblast differentia-
tion (Serini and Gabbiani, 1999). Furthermore, most previ-
ously known stimulators of myofibroblast differentiation ap-
pear to act indirectly through TGF
 
 
 
1 (Serini and Gabbiani,
1999). Whether cCAF can stimulate 
 
 
 
-SMA independently
of TGF
 
 
 
 is not known. However, the fact that this chemo-
kine stimulates 
 
 
 
-SMA expression shortly after treatment is
initiated, and that it stimulates signals through G-protein–
coupled receptors, whereas TGF
 
 
 
1 elicits its effects through
Figure 7. Inhibition of  -SMA expression using oligonucleotides. 
(A) Phosphorothioate antisense ODN were used to inhibit  SMA 
expression. The sequence of ODN is provided in Materials and 
methods. When preparing the collagen gels, 2  M of antisense or 
sense ODN were incorporated into the gel before the seeding of 
CEFs. The treatments to induce gel contraction were performed as in 
Fig. 6, A–F, except that 2  M of antisense or sense ODN was added 
each time the chemokine or peptide was applied. The ODN 
strongly inhibited gel contraction stimulated by cCAF or the 
N-peptide. (B) Immunoblot analysis of  SMA production in the 
gels from the experiments in A.
Figure 8. Stimulation of  -SMA expression in cells treated with 
cCAF. Fibroblasts treated with cCAF show rapid increase of  -SMA 
mRNA, peaking at 3 h and declining by 24 h. Total RNA extracted 
using TRIzol reagent and RT-PCR was performed as described in 
Materials and methods. A fragment of the 18S rRNA was used as 
control to normalize the amount of  -SMA. 
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serine kinase receptors, suggests that they stimulate different
signal transduction pathways to activate 
 
 
 
-SMA expression.
Nevertheless, it is possible that these signal transduction
pathways share common downstream signaling molecules.
We are currently investigating the molecular mechanisms of
cCAF-induced 
 
 
 
-SMA production, whether the human ho-
mologues of cCAF function in the same manner, and how
they relate to the signaling mechanisms stimulated by TGF
 
 
 
.
Cells containing 
 
 
 
-SMA (myofibroblasts, smooth muscle
cells, and pericytes) play important functions in a variety of
processes involved in wound healing, vasculogenesis/angio-
genesis, and pathological conditions, especially in diseases
that are characterized by excess scarring. In wound healing,
myofibroblasts are particularly important in wound closure
and contraction. For example, lack of myofibroblasts after
corneal surgery leads to corneal flattening and widening of
the wound, whereas stimulation of myofibroblast differenti-
ation in noncontractile fetal wounds leads to contraction of
the wounds (Jester et al., 1999; Lanning et al., 2000). In dis-
ease states characterized by an accumulation of myofibro-
blasts, such as pulmonary fibrosis and scleroderma, myofi-
broblasts are thought to contribute significantly to the
pathology of the disease, primarily because myofibroblasts
tend to be highly fibrogenic (Powell et al., 1999). In addi-
tion, myofibroblasts are present in the stroma of many tu-
mors and appear to be important for the survival of these tu-
mors (Coffin et al., 1998; Schürch et al., 1998).
In addition to stimulating wound closure through the dif-
ferentiation of myofibroblasts, cCAF may also be acting to
increase the stability of new blood vessels in the granulation
tissue. Smooth muscle cells of the new vasculature are
known to differentiate from mesenchymal cells in response
to signals from the endothelial cells (e.g., Carmeliet, 2000).
These smooth muscle cells are essential for vascular matura-
tion in connective tissue (Carmeliet, 2000). CXC chemo-
kines are produced by the endothelial cells and fibroblasts of
the connective tissue and promote angiogenesis (Martins-
Green and Bissell, 1990; Martins-Green et al., 1991, 1992;
Martins-Green and Feugate, 1998; Belperio et al., 2000).
These chemokines are known to affect endothelial cell mi-
gration, but part of their role in the formation of new blood
vessels may be in stimulating fibroblasts to acquire 
 
 
 
-SMA
and become the smooth muscle cells that stabilize the newly
formed vasculature (unpublished data).
Because myofibroblast accumulation is prominent and
high levels of chemokines are present in conditions charac-
terized by excessive scarring, such as keloids, scleroderma,
and pulmonary fibrosis (Zhang et al., 1996; Nedelec et al.,
Figure 9. Accelerated closure of 
wounds treated with cCAF or with 
N-peptide. Excision wounds were made 
on the underside of chick wings and 
then treated every other day with vehicle 
(H2O) or 1  g cCAF. The dashed lines 
trace the edges of the wounds. The 
underlying muscle can be seen within 
the wounds. Control wings (A and C) 
show less wound closure at day 3 than 
cCAF-treated wounds (B and D). Dashed 
straight lines mark the length of the 
forewings to facilitate evaluation of the 
size of the wounds. (E) Average percent 
wound closure in eight birds for cCAF or 
vehicle treatment. (F) Average percent 
wound closure of eight birds/treatment 
with N-peptide or vehicle. Areas of the 
wounds were measured on digital 
photographs using NIH Image software. 
Percentage wound closure was calculated 
by comparing the area of the closing 
wound to the area of the same wound 
on day 0. At day 3, P   0.05 for both 
treatments. 
cCAF stimulates myofibroblast differentiation |
 
 Feugate et al. 169
 
1998), it is possible that chemokines may participate in such
diseases by stimulating myofibroblast differentiation. For ex-
ample, levels of MCP-1, IL-8, and MIP-1
 
 
 
 are high in pul-
monary fibrosis (Keane et al., 1997; Hasegawa et al., 1999).
These chemokines are also elevated in sclerotic tissue (Ka-
dono et al., 1998; Hasegawa et al., 1999). Myofibroblasts in
keloids express MGSA, whereas the cells of normal scars do
not (Nirodi et al., 2000). Our results suggest that some of
the problems in these conditions may be due to the high lev-
els of chemokines, leading to an increase in myofibroblast
numbers, excess deposition of matrix molecules, and con-
traction of the tissue.
Controlling the differentiation of myofibroblasts could
mitigate the effects of fibrotic and other diseases. CXC
chemokines could be suitable for this purpose because they
are not constitutively expressed and do not have the broad-
ranging effects that TGF
 
 
 
1 does. In addition, chemokines
are very small molecules with no modification other than
disulfide bonds, therefore they can be produced using re-
combinant approaches without much difficulty and they
bind to 7-transmembrane receptors, which are highly ame-
nable to pharmacological manipulations. As a consequence,
once the mode of action of these proteins on 
 
 
 
-SMA expres-
sion is deciphered, they or their antagonists could be used to
modulate the presence of myofibroblasts in both disease
states and in abnormal wound healing. Furthermore, the
ability of the 15 amino acid NH
 
2
 
-terminal peptide to stimu-
late effects similar to those stimulated by the whole cCAF
molecule strongly suggests that the peptide itself or peptide
mimetics could be used for treatment of wounds with im-
paired closure.
In conclusion, a major role of cCAF in the granulation
tissue development may be the stimulation of proper
wound closure through the stimulation of myofibroblast
differentiation. This is a previously unknown function for
chemokines and it could represent a novel mechanism for
the induction of myofibroblast differentiation. In addition,
our results may explain why chemokines contribute to the
Figure 10. Histology of excision wounds treated with cCAF. 
Paraffin-embedded sections of excision wounds treated every other 
day with vehicle or 1  g cCAF were stained with Masson Trichrome. 
At 3 d after wounding, control wounds (A) have much less dense 
granulation tissue than those treated with cCAF (B). By day 5, the 
granulation tissue of the control wounds (C) resembles the tissue of 
the treated wounds at day 3 (B). The cCAF-treated wounds continue 
to have denser repair tissue than the control wounds on day 5 (D). 
By day 7, the difference between the control wounds (E) and cCAF-
treated wounds (F) is greatly diminished. Bar, 25  m.
Figure 11. Immunostaining for  -SMA in the granulation tissue of 
excision wounds treated with cCAF. Paraffin-embedded sections of 
excision wounds treated every other day with vehicle or 1  g cCAF 
were immunostained with an antibody against  -SMA. At 3 d after 
wounding, control wounds (A) show almost no cells labeling for 
 -SMA, whereas those treated with cCAF show already a significant 
number of cells labeling for  -SMA (B). At day 5, both controls (C) 
and cCAF-treated wounds (D) show more cells expressing  -SMA, 
with cCAF-treated wounds showing a much greater increase. By 
day 7, cCAF-treated wounds (F) continue to have more labeled cells 
than do control wounds (E), but the difference is greatly diminished. 
(G) Quantitation of the data in A–F (see Materials and methods 
for quantitation procedures). Triple asterisk indicates P   0.001. 
Bar, 88  m. 
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pathology of fibrotic diseases in which myofibroblasts play
a significant part.
 
Materials and methods
 
Materials
 
All tissue culture media and materials were purchased from GIBCO BRL.
cCAF was either purified as described in Martins-Green and Feugate
(1998) or synthesized by Gryphon Sciences. The 16 amino acid NH
 
2
 
-ter-
minal peptide was also synthesized by Gryphon Sciences. The 28 amino
acid COOH-terminal peptide was synthesized by Milligen Biosearch. Anti-
bodies used were: anti–
 
 
 
-SMA (Sigma-Aldrich); anti-TGF
 
 
 
 1,2,3 (R&D
Systems); antivimentin, antidesmin, antimyosin heavy chain (Hybridoma
Bank); anti-myoD (Santa Cruz Biotechnology, Inc.); anti–mouse horserad-
ish peroxidase, anti–mouse Texas red (Amersham Pharmacia Biotech);
anti–mouse Alexa (Molecular Probes); and anti–mouse FITC (Dako). The
anti-cCAF rabbit serum was prepared by Robert Sargeant (Ramona, CA).
Other materials used include: nuclear staining To-Pro3 (Molecular
Probes), ECL reagents (Amersham Pharmacia Biotech), Vectashield mount-
ing medium (Vector Laboratories), DC protein assay kit (Bio-Rad Laborato-
ries), TRIzol reagent (GIBCO BRL), Vitrogen 100 collagen (Cohesion Tech-
nologies), Biocclusive bandage (Johnson and Johnson Medical); and
Classic 18S rRNA primers (Ambion). TGF
 
 
 
1 was a gift from A. Roberts
(National Institutes of Health, Bethesda, MD).
 
Cell cultures
 
Primary chicken embryonic connective tissue fibroblasts (CEFs) were cul-
tured as described previously in Martins-Green and Feugate (1998).
Briefly, these fibroblasts were isolated from 10-d-old chicken embryo body
walls, plated at 6 
 
 
 
 10
 
6
 
 cells/100-mm plate and cultured for 4 d in 199
medium with 5% donor calf serum, 1% chick serum, and 0.3% tryptose
phosphate broth. These cultures were passaged once (secondary cultures);
the cells were plated at 0.4 
 
  
 
10
 
6
 
 cells/35-mm plate in 199/tryptose phos-
phate broth and 2% donor calf serum.
 
Fibroblast growth assay
 
Secondary fibroblasts were plated at 0.4 
 
 
 
 10
 
6
 
 cells/35-mm plate and
cCAF was added to experimental plates. For each experiment, plating effi-
ciency was determined by trypsinizing plates 4 h after plating. Cells were
counted with a Coulter particle counter to confirm even plating of cells.
The media was replaced approximately every 16 h with 1 ml of serum-free
199 medium containing 0.3% tryptose phosphate broth and 2% donor calf
serum, and 100–1,000 ng cCAF (9–90 nM) or C- or N-peptide (64–640
nM) was added to the experimental plates, whereas control plates con-
tained media only. On day 3, plates were trypsinized to remove all cells
and cells were counted using a Coulter counter. To test for specificity, anti-
cCAF rabbit serum was preincubated with cCAF (3 
 
 
 
l serum/750 ng cCAF
[68 nM] or N-peptide [480 nM]) for 1 h at room temperature before being
added to cells.
 
Trypan blue staining
 
The supernatant of treated and untreated CEFs was collected and the cells
centrifuged to a pellet and resuspended in a small volume of medium. 1%
trypan blue was added to a final concentration of 0.5% trypan blue. Cells
were stained for 5 min and then counted in a hemocytometer. Necrotic
cells stained blue.
 
Apoptosis assay
 
To detect cCAF-induced apoptosis we used the DNA Laddering Detection
System from Roche Biochem. Fibroblasts were plated, treated as described
above, and the DNA was prepared as suggested by the manufacturer.
Briefly, at the end of each treatment, cells were trypsinized, pelleted, re-
suspended in binding buffer, and incubated for 10 min at room tempera-
ture. After this incubation period, isopropanol was added and the prepara-
tion vortexed and passed through a filter tube with glass binding fleece.
The samples were then centrifuged for 1 min at 8,000 rpm, the flow
through was discarded, and the DNA retained in the fleece was washed
two times with wash buffer and then eluted with prewarmed elution buffer
and used for agarose gel electrophoresis.
 
Immunostaining for 
 
 
 
-SMA
 
Plates of fibroblasts were treated with cCAF as described previously. After
4 d, the cells were rinsed with PBS, fixed in 4% paraformaldehyde, perme-
abilized with 0.15% Triton X-100, and incubated with PBS containing
0.1 M glycine for 10 min. Cells were blocked for 30 min with 10% goat se-
rum in PBS, incubated with mouse anti–
 
 
 
-SMA to a final IgG concentration
of 20 
 
 
 
g/ml in 1% BSA/PBS for 1 h at room temperature, and washed three
times with 0.1% BSA/PBS for 10 min each. The cells were then incubated
in To-Pro3 (1:1,000) and goat anti–mouse FITC or sheep anti–mouse Texas
red (1:100) in 1% BSA/PBS for 1 h at room temperature, washed three
times for 10 min with 0.1% BSA in PBS, and mounted with Vectashield.
Confocal fluorescence microscopy was performed on a ZEISS LSM510.
Collagen gels were rinsed with PBS, fixed in 4% paraformaldehyde for 2 h,
washed three times 30 min each with PBS, and incubated for an additional
30 min in PBS containing 0.1 M glycine. This treatment was followed by
incubation at 4
 
 
 
C O/N in 15% sucrose and then incubation under the
same conditions in 30% sucrose. After a brief rinse with PBS, the gels were
frozen in OCT, sections were prepared and collected on gelatin-coated
slides, rinsed with PBS, fixed in 4% paraformaldehyde for 10 min, and
then incubated again in PBS containing 0.1 M glycine for 10 min. This was
followed by blocking for 30 min with 10% goat serum in PBS, incubation
in primary and secondary antibody as described above, and mounting
with Vectashield.
 
Immunoblotting
 
Plates of fibroblasts were treated as described previously with 750 ng/ml
cCAF or 2.5 ng/ml TGF
 
 
 
. To block TGF
 
 
 
 or cCAF activity, anti-cCAF (3 
 
 
 
l)
or anti-TGF
 
 
 
 (1 
 
 
 
l) antibody was preincubated in 1 ml media for 1 h at
room temperature before being added to cells. After 4 d of treatment, pro-
tein extracts were prepared in 1 ml 150 mM RIPA buffer containing pro-
tease inhibitors. Protein concentrations were determined using the DC
protein assay kit and samples were adjusted to contain equal amounts of
protein. SDS-PAGE was performed on 7.5% separating Doucet gels (Dou-
cet and Trifaro, 1988). Protein transfer to nitrocellulose was performed us-
ing a wet-transfer apparatus (Bio-Rad Laboratories) at 100 V for 45 min.
The membranes were blocked for 1 h in 5% milk in TTBS and then incu-
bated overnight at 4
 
 
 
C in anti–
 
 
 
-SMA (1:1,500), antivimentin (1:100), anti-
desmin (1:100), antimyosin heavy chain (1:100), or anti-myoD (1:200) in
1% milk in TTBS. The membranes were washed three times for 20 min
each with TTBS, incubated in anti-mouse HRP at 1:10,000 in 1% milk for
1 h, and washed as above; and the bands were visualized using the ECL.
 
Collagen gel contraction
 
1.5 ml Vitrogen 100 collagen gels were made in 35-mm plates. Secondary
fibroblasts were plated at 0.4 
 
 
 
 10
 
6
 
 cells/35-mm plate on top of the gels.
After the cells had adhered to the collagen, cCAF was added to experimen-
tal plates. The medium was replaced approximately every 16 h with 1 ml
of 199 supplemented with 0.3% tryptose phosphate broth and 2% donor
calf serum, and 750 ng cCAF (68 nM) or N-peptide (480 nM) was added to
the experimental plates. Control plates contained media only. After 4 d,
gels were released. Treatment was continued for two more days and gels
were photographed every 12 h. The photographs were used for evaluation
of gel contraction by determining the area of the gel using NIH image anal-
ysis. For the experiments involving inhibition of 
 
 
 
-SMA expression, we
used phosphorothioate antisense ODN, which was synthesized and HPLC
purified by Sigma-Aldrich Genosys, to block the 
 
 
 
-SMA production. The
sequence of ODN is specific for the 3
 
 
 
-untranslated region of 
 
 
 
-SMA (5
 
 
 
-
CACAGTAATATGCTAAAAAGAC-3
 
 
 
) as described previously (Ronnov-
Jessen and Petersen, 1996; Nakajima et al., 1999). The sense strand of this
ODN was used as control (5
 
 
 
-GTCTTTTTAGCATATTACTGTG-3
 
 
 
). When
preparing the collagen gels, 2 
 
 
 
M of antisense or sense ODN were incor-
porated into the gel before the seeding of CEFs. The treatments and mea-
surement of gel contraction were performed as described above, except
that 2 
 
 
 
M of antisense or sense ODN were applied each time the chemo-
kine or peptide was applied.
 
RT-PCR
 
Total RNA for 
 
 -SMA was extracted using TRIzol reagent from untreated fi-
broblasts, fibroblasts treated with 750 ng/ml cCAF, or fibroblasts treated for
varying periods of time with cCAF. The RT-PCR procedure was performed
using the Promega Access RT-PCR System, which is designed to finish RT
and PCR in one tube and following the protocol recommended by
Promega, except that 1.5 times the recommended amount of dNTP, re-
verse transcriptase, and Tfl DNA polymerase were used to ensure strong
synthesis of 18S ribosomal RNA. The reaction conditions included: 1  g
total RNA, first strand synthesis at 48 C for 45 min, then 95 C for 5 min to
inactivate the reverse transcriptase, followed by DNA amplification at
95 C for 45 s, 58 C for 60 s, 68 C for 90 s for 40 cycles. Finally, 68 C for 7
min to extend the strands. 3  l of Quantum mRNA classic 18S primers
(Ambion) were added to the reaction to produce the control band. ThecCAF stimulates myofibroblast differentiation | Feugate et al. 171
primers used for the amplification of  -SMA were: sense primer 5 -GGAG-
CACCTGAGGACATTGAC-3  and antisense primer 5 -GCTTCAGTCAG-
CAGAGTTGGG-3 . RT-PCR products were analyzed by electrophoresis in
1.5% agarose and the density of the bands was measured by densitometry
using Glyko BandScan.
Wounding experiment
Full-thickness excision wounds ( 0.5   0.5 cm) were made using a scal-
pel blade on the underside of the wings of 2-wk-old chicks. The left wing
was treated with vehicle alone (water) and the right wing with 1  g cCAF
(90 nM). The wounds were photographed immediately after wounding and
then covered with Biocclusive bandage. 50  l vehicle (water) or cCAF was
deposited through the bandage onto the wound using a 30-gauge needle.
This procedure was repeated the next day and every other day thereafter.
On days 3, 5, and 7 the bandages were removed and the wounds were
photographed before replacing the bandages and applying the treatment
again. Wings were placed on a flat surface at a distance of 25 cm from the
digital camera and were always photographed with the same camera set-
tings. All images were printed at the same magnification.
Preparation and staining of wing sections
At the specified time points, chickens were killed with sodium pentobarbi-
tol. The wounded wings were collected and fixed for 18 h in 4% parafor-
maldehyde and decalcified for 3 d in 5% formic acid, 2.5% formaldehyde
at 4 C. The tissue was embedded in paraffin and sectioned. Sections were
stained with Masson Trichrome to visualize interstitial collagen. Other sec-
tions were immunolabeled for  -SMA. Sections were deparaffinized three
times with 15 min washes in Hemo-De and rehydrated in 5 min washes of
ethanol (100, 95, 70, 50, and 30%). After rinsing with PBS, sections were
fixed in 2% paraformaldehyde 1 h. Autofluoresence and nonspecific stain-
ing was blocked by 30 min in 0.1 M glycine in PBS, followed by 30 min in
1% Evans Blue in PBS to quench red blood cell autofluorescence. Sections
were incubated with  -SMA antibody in 1% BSA in PBS (1:50) for 2 h at
room temperature. After three 10 min washes in 0.1% BSA in PBS, the sec-
tions were incubated for 40 min with anti–mouse Alexa antibody in 1%
BSA in PBS (1:200). They were then washed and mounted with Vecta-
shield. To quantify the number of myofibroblasts in the wounds, the num-
ber of fluorescently labeled cells in four high power fields of each wound
was counted and statistical analysis was applied.
Statistical methods
Significance was determined using Student’s t test for comparison between
two means and ANOVA for comparison between more than two means.
All data were examined to assure homogeneity of variance. Means were
considered significantly different when P   0.05.
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